Neuropsychological differences but comparable regional cerebral blood changes in asymptomatic HIV-1-positive and -negative drug addicts.
The objective of this study was to characterize the cognitive status of a population of asymptomatic HIV-positive drug addicts (patient group) to document the relationship between neuropsychological results and cerebral blood flow defects as measured by single photon emission computed tomography. As a control group we employed an age-matched population of HIV-seronegative drug addicts. Some neuropsychological differences were found between patients and controls and between drug addicts and normal population. We could not detect any difference in cerebral blood flow rates among HIV-1-positive and -negative drug addicts.
Beldarrain
M G
MG
Sección de Neurología, Hospital de Galdacano, Vizcaya, Spain.
García-Moncó
J C
JC
Llorens
V
V
Cortés
J
J
Mayo
J
J
D015526:AIDS Dementia Complex / Q000175:diagnosis* / Q000503:physiopathology; D001921:Brain / Q000098:blood supply*; D002540:Cerebral Cortex / Q000098:blood supply; D003937:Diagnosis, Differential; D004292:Dominance, Cerebral / Q000502:physiology; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000175:diagnosis* / Q000503:physiopathology; D015497:HIV-1; D006801:Humans; D009483:Neuropsychological Tests; D015609:Organotechnetium Compounds; D010091:Oximes; D012039:Regional Blood Flow / Q000502:physiology; D015819:Substance Abuse, Intravenous / Q000150:complications* / Q000503:physiopathology; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000503:physiopathology; D019690:Technetium Tc 99m Exametazime; D015899:Tomography, Emission-Computed, Single-Photon
D015609:Organotechnetium Compounds; D010091:Oximes; D019690:Technetium Tc 99m Exametazime